Key Points
- CAO Kathryn Romano sold 12,500 shares on Feb. 9 at an average price of $272.14 for a total of $3,401,750, cutting her position by 39.29% to 19,318 shares (≈$5.26M remaining).
- Krystal Biotech (NASDAQ:KRYS) trades near $272 with a market cap of about $7.91B and a PE of 40.9; analysts have a consensus “Moderate Buy” with an average target of $277.89 and several firms recently raising targets (Citigroup to $336).
Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) CAO Kathryn Romano sold 12,500 shares of the business's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $272.14, for a total value of $3,401,750.00. Following the completion of the transaction, the chief accounting officer directly owned 19,318 shares in the company, valued at approximately $5,257,200.52. The trade was a 39.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Krystal Biotech Price Performance
Shares of NASDAQ KRYS opened at $272.65 on Thursday. The stock has a fifty day moving average price of $260.24 and a 200 day moving average price of $204.03. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $295.98. The company has a market cap of $7.91 billion, a PE ratio of 40.88 and a beta of 0.49.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on KRYS. Citigroup lifted their target price on shares of Krystal Biotech from $320.00 to $336.00 and gave the company a "buy" rating in a report on Monday, January 12th. Chardan Capital lifted their price objective on Krystal Biotech from $216.00 to $220.00 and gave the company a "buy" rating in a report on Tuesday, November 4th. Weiss Ratings reiterated a "hold (c+)" rating on shares of Krystal Biotech in a research report on Monday, December 29th. HC Wainwright reissued a "buy" rating and issued a $310.00 price target (up from $240.00) on shares of Krystal Biotech in a report on Friday, January 9th. Finally, Guggenheim set a $224.00 price target on Krystal Biotech and gave the company a "buy" rating in a research note on Friday, October 17th. Nine investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Krystal Biotech currently has a consensus rating of "Moderate Buy" and an average target price of $277.89.
Check Out Our Latest Research Report on Krystal Biotech
Institutional Trading of Krystal Biotech
A number of institutional investors have recently bought and sold shares of KRYS. Sound Income Strategies LLC raised its stake in shares of Krystal Biotech by 1,270.0% during the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company's stock worth $34,000 after buying an additional 127 shares during the last quarter. Bessemer Group Inc. increased its holdings in Krystal Biotech by 106.9% during the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company's stock valued at $26,000 after acquiring an additional 77 shares in the last quarter. Global Retirement Partners LLC increased its holdings in Krystal Biotech by 788.9% during the 4th quarter. Global Retirement Partners LLC now owns 160 shares of the company's stock valued at $39,000 after acquiring an additional 142 shares in the last quarter. AdvisorNet Financial Inc acquired a new position in Krystal Biotech during the third quarter worth about $30,000. Finally, Hantz Financial Services Inc. lifted its holdings in shares of Krystal Biotech by 8,950.0% in the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company's stock valued at $25,000 after purchasing an additional 179 shares in the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.
Krystal Biotech Company Profile
(
Get Free Report)
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
